Myfortic (Mycophenolic Acid)

Mycophenolic acid, the active ingredient in Myfortic, is an immunosuppressant presented as an oral formulation for oral use. It works by inhibiting lymphocyte proliferation and is prescribed to prevent organ transplant rejection in adult patients receiving kidney, heart, or liver transplants, and is part of standard immunosuppressive regimens.

GNH USA supplies Myfortic as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres and pharmacies worldwide. Our distribution network ensures consistent quality and regulatory compliance across EU and global markets.

Myfortic is used in the immunosuppressive pathway to prevent rejection of transplanted organs.

Organ transplant rejection prevention: Reduces the risk of acute and chronic rejection in kidney, heart, liver and other solid organ transplants.

Myfortic may be associated with a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Diarrhea: loose stools. - Headache: tension‑type discomfort. - Infections: increased susceptibility to common viral or bacterial infections.

Serious or Rare Side Effects: - Leukopenia: significant reduction in white blood cell count. - Severe infection: opportunistic infections such as Pneumocystis jirovecii pneumonia. - Gastrointestinal perforation: rare but life‑threatening ulceration.

When prescribing Myfortic, clinicians should consider several precautionary measures to minimize risk.

- Monitor blood counts: regular complete blood count testing to detect leukopenia. - Assess renal function: adjust therapy if creatinine clearance declines. - Evaluate infection risk: screen for latent viral infections before initiation. - Avoid live vaccines: immunosuppression may reduce vaccine efficacy. - Pregnancy and lactation: use only if benefits outweigh risks; discuss with obstetric specialist. - Store at ambient temperature: keep below 25 °C, retain in original container, protect from moisture and light.

Myfortic can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Antacids containing aluminum or magnesium: reduce absorption of mycophenolic acid. - Cyclosporine: increases mycophenolic acid exposure, raising toxicity risk. - Rifampin: markedly decreases mycophenolic acid levels, compromising efficacy.

Moderate Interactions (Monitor Closely): - Azathioprine: additive bone‑marrow suppression. - Valganciclovir: may increase risk of cytopenias. - Cholestyramine: can bind and lower drug concentration.